Do you have a link to a PR or filing that discusses this? Or was it discussed at a conference....
I believe you, but I'd like some independent confirmation.
BTW - I listened to the CC again, and the sales increase for FY05 has fully factored in the 26% price increase. Management decided to be conservative with regards to actual organic growth via prescriptions, hence the "conservative" guidance of sales growth of 37-46% y/y. Q1 scripts were +22% over the same time frame in Q1 of last year.
Also, it appears that there was some restocking of the product by wholesalers during Q1; that was completed by the end of the quarter, according to the company.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.